Aelan Cell Technologies today announced the development of a novel epigenetic biomarker. An early human clinical feasibility study has indicated that serological tests using the biomarker alongside other proprietary components developed by Aelan’s researchers could potentially help physicians diagnose Alzheimer’s disease (AD).
from Dementia Big http://ift.tt/29Ag2tV via alcoholic dementia
http://ift.tt/29CWnd7
No comments:
Post a Comment